Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: Eli lilly - Caught on Camera

Two Drugmakers Paid More Than a Quarter Million American Prescribers as Weight Loss Drug Sales Climbed

An analysis of federal payment data found Eli Lilly and Novo Nordisk paid over 250,000 US prescribers as GLP-1 weight loss drug sales grew.

Medical Daily

Can a New Weight Loss Treatment Escape the Legal and Regulatory Thicket?

It’s Eli Lilly vs. RFK Jr. in a battle over the rules around retatrutide.

Reason

A $2.88 Billion Reason Why Eli Lilly Stock Is in Focus Today

Eli Lilly announced a $2.88 billion acquisition of Merida Biosciences. Here’s what it means for LLY shares.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

‘Who knows what they’re taking?’: people risk the gray market for the newest weight-loss drug

Retatrutide, not yet approved by the FDA, is the latest wonder drug to shed pounds despite warnings from doctors

The Guardian - US

Eli Lilly diabetes drug wins FDA approval to lower cardiovascular risks

Heart disease is is the leading cause of death for people with Type 2 diabetes

The Independent UK

Eli Lilly’s Mounjaro wins FDA approval for a major new cardiovascular benefit

Eli Lilly's Mounjaro received FDA approval for reducing heart attack and stroke risks. This new indication expands its use beyond diabetes and weight management. The drug demonstrated an 8% greater reduction in cardiovascular events in a key study. Mounjaro's approval strengthens Eli Lilly's position in the GLP-1 medicine market. This…

The Economic Times

No GLP-1 Is Approved for Addiction and the Trials That Could Change That Do Not Report Until 2027

GLP-1 drugs show real anti-craving signals, but no approval exists for addiction, and the decisive trial results are still years away.

Medical Daily

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly Presses Payment Processors and Social Platforms as Federal Enforcement Struggles to Slow Retatrutide Sales

With FDA enforcement stalled at the warning-letter stage, Lilly is pressuring credit card companies and social media platforms to cut off retatrutide sellers.

Medical Daily

An Amino Acid Dispute Between Eli Lilly and the FDA Could Delay Cheaper Retatrutide by Years

A federal court fight over whether retatrutide counts as a biologic will decide if patients wait 12 years or five for cheaper competition.

Medical Daily

Weight-loss pill Foundayo is now available in UK pharmacies

IN FULL

The Independent UK

New daily diabetes pill that helps with weight loss launches in UK pharmacies

Foundayo will be available on private prescription, with pharmacists warning of counterfeit GLP-1 problem

The Guardian - UK

Foundayo: New once-daily weight loss pill now available in pharmacies across UK

The UK was the first country in Europe to approve Foundayo

The Independent UK

2 Biotech Stocks Shaping Up for Major Breakouts

Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.

MarketBeat

How the Gila Monster's Saliva Became a Diabetes Drug Now Used by Millions Worldwide

The lizard that never eats, yet never crashesThe Gila Monster can go up to a year without a meal. That is not hyperbole, it is a documented biological fact about one of only two venomous lizard species native to North America. During those long stretches of fasting, its blood glucose…

Times Life

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

Prescription Drug Prices Fell 3.1 Percent Over the Year, but That Number Measures Less Than You Think

Prescription drug prices posted their steepest annual drop since 1963. Here is what the index actually measures and what it leaves out.

The Independent UK

New type 2 diabetes jab could slash number of injections to one a week

The treatment, also known as Onswik and made by Eli Lilly, is said to work as well as daily injections

Evening Standard

Firms face pressure from shifting demand after weight-loss pills approved

New research found 34% of Britons would consider taking weight loss medication in tablet form rather than injections.

Bored Panda

Hollywood’s “Getting Thinner” Trend Raises Concern As Jenna Ortega Becomes The Latest Celebrity To Worry Fans

"The next Ariana Grande."

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

The Obesity Drug Race Moves Past Ozempic with a Shot Targeting Three Hormones

Eli Lilly's retatrutide produced up to 30.3% average weight loss in phase 3 trials. Approval is not expected before 2027 at the earliest.

The Economic Times

UK first in Europe to approve Eli Lilly oral weight loss drug

Britain has become the first country in Europe to approve orforglipron, the oral weight loss and diabetes treatment developed by US company Eli Lilly, the UK government has revealed. Eli Lilly's Mounjaro weight loss drug, like Wegovy, is injected. bcp/ajb/st

The Independent UK

Foundayo: The new weight loss pill approved for the UK

Foundayo has been approved for treating weight loss as well as type 2 diabetes

The Economic Times

Eli Lilly’s Foundayo becomes first oral weight-loss drug approved in UK for diabetes

Britain's regulator approved Eli Lilly's Foundayo pill for weight and diabetes. This treatment is not yet available through the NHS in the UK. Foundayo will launch privately later this month via prescription. Novo Nordisk's Wegovy pill also received approval for the UK market. The weight-loss drug market is seeing increased…

The Independent UK

New once-daily weight loss pill approved by the UK medicines regulator

The UK has become the first country in Europe to authorise orforglipron, known as Foundayo

Fortune

Weight loss drug Wegovy made Novo Nordisk Europe’s most valuable company. Finding its next blockbuster drug is proving difficult

A clinical trial failure and U.S. competition have been tough for the Danish pharmaceutical firm. CFO Karsten Munk Knudsen says the company is doubling down on innovation and its weight loss pills as it looks toward its next stage of growth.

Barchart

Eli Lilly Stock: Analyst Estimates & Ratings

Eli Lilly's market-beating performance has done little to temper Wall Street's optimism, with analysts continuing to see meaningful upside in the stock.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Justice Department

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.